Loading...
•
Sep 30, 2020
Veracyte Q3 2020 Earnings Report
Veracyte's Q3 2020 financial results showed a rebound to pre-pandemic levels, driven by the Afirma franchise, and key reimbursement and clinical-evidence milestones were achieved.
Key Takeaways
Veracyte announced a strong rebound in business during the third quarter, with revenue returning to pre-pandemic levels at $31.1 million. The company achieved important reimbursement and clinical-evidence milestones and remains on track to launch four new clinical products in 2021.
Revenue for the third quarter of 2020 was $31.1 million.
Product and testing revenue increased by 79% over the second quarter of 2020.
Gross Margin was 67% for the third quarter of 2020.
Net Loss and Comprehensive Loss was $4.1 million for the third quarter of 2020.
Veracyte
Veracyte
Veracyte Revenue by Segment
Revenue by Segment
Testing Revenue
CapyFin.comBiopharmaceutical and Other Revenue
CapyFin.com Forward Guidance
Due to the continued uncertainties with respect to the COVID-19 pandemic, the company will not be providing guidance at this time.
Revenue & Expenses
Visualization of income flow from segment revenue to net income